JP2008522666A - 癌のためのｍｒｉガイド下光線力学的療法 - Google Patents

癌のためのｍｒｉガイド下光線力学的療法 Download PDF

Info

Publication number
JP2008522666A
JP2008522666A JP2007544609A JP2007544609A JP2008522666A JP 2008522666 A JP2008522666 A JP 2008522666A JP 2007544609 A JP2007544609 A JP 2007544609A JP 2007544609 A JP2007544609 A JP 2007544609A JP 2008522666 A JP2008522666 A JP 2008522666A
Authority
JP
Japan
Prior art keywords
contrast agent
target tissue
mri
polymer
delivery system
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2007544609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008522666A5 (enExample
Inventor
チェン−ロン ルー
アナハ ヴィアディア
ティアンイ キー
Original Assignee
ユニバーシティー オブ ユタ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ユニバーシティー オブ ユタ リサーチ ファンデーション filed Critical ユニバーシティー オブ ユタ リサーチ ファンデーション
Publication of JP2008522666A publication Critical patent/JP2008522666A/ja
Publication of JP2008522666A5 publication Critical patent/JP2008522666A5/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/146—Peptides, e.g. proteins the peptide being a polyamino acid, e.g. poly-lysine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Radiology & Medical Imaging (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Laser Surgery Devices (AREA)
  • Radiation-Therapy Devices (AREA)
JP2007544609A 2004-12-03 2005-12-02 癌のためのｍｒｉガイド下光線力学的療法 Withdrawn JP2008522666A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63325504P 2004-12-03 2004-12-03
PCT/US2005/044012 WO2006060797A2 (en) 2004-12-03 2005-12-02 Mri guided photodynamic therapy for cancer

Publications (2)

Publication Number Publication Date
JP2008522666A true JP2008522666A (ja) 2008-07-03
JP2008522666A5 JP2008522666A5 (enExample) 2009-01-29

Family

ID=36565853

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007544609A Withdrawn JP2008522666A (ja) 2004-12-03 2005-12-02 癌のためのｍｒｉガイド下光線力学的療法

Country Status (9)

Country Link
US (1) US20090076571A1 (enExample)
EP (1) EP1830879B1 (enExample)
JP (1) JP2008522666A (enExample)
KR (1) KR20070086803A (enExample)
AT (1) ATE485836T1 (enExample)
AU (1) AU2005311560A1 (enExample)
CA (1) CA2589881A1 (enExample)
DE (1) DE602005024437D1 (enExample)
WO (1) WO2006060797A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012529500A (ja) * 2009-06-12 2012-11-22 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 癌の光線力学療法のための標的化されたナノフォトメディスン

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2206736B1 (en) 2005-12-05 2012-02-08 Nitto Denko Corporation Polyglutamate-amino acid conjugates and methods
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
JP2010526159A (ja) * 2007-04-10 2010-07-29 日東電工株式会社 多機能性ポリグルタミン酸塩薬物担体
EP2155253A2 (en) * 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
WO2009055542A1 (en) * 2007-10-26 2009-04-30 University Of Utah Research Foundation Use of mri contrast agents for evaluating the treatment of tumors
WO2013119957A1 (en) * 2012-02-10 2013-08-15 Aidan Research And Consulting, Llc Weight reduction through inactivation of gastric orexigenic mediator producing cells
TW201514188A (zh) * 2013-03-13 2015-04-16 Lantheus Medical Imaging Inc 製備釓磷維塞三鈉單水合物之方法
CN114870014B (zh) * 2022-05-18 2023-07-07 南京邮电大学 一种多功能抗肿瘤高分子药物及其制备方法和用途
WO2025160349A1 (en) * 2024-01-25 2025-07-31 Ovokaitys Todd Frank Methods and systems for improving photodynamic therapy by increasing depth of penetration without concurrently increasing energy deposition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5594136A (en) * 1989-12-21 1997-01-14 Pharmacyclics, Inc. Texaphyrin solid supports and devices
WO1998026747A2 (en) * 1996-12-17 1998-06-25 Terman David S Superantigen based methods and compositions for treatment of diseases
DE19831217A1 (de) * 1998-07-03 2000-01-05 Schering Ag Neue Porphyrinderivate, diese enthaltende pharmazeutische Mittel und ihre Verwendung in der photodynamischen Therapie und MRI-Diagnostik
US6534040B2 (en) * 1999-12-23 2003-03-18 Health Research, Inc. Chlorin and bacteriochlorin-based aminophenyl DTPA and N2S2 conjugates for MR contrast media and radiopharmaceuticals
WO2002087632A1 (en) * 2001-05-02 2002-11-07 Metaprobe, Inc. High throughput screening methods using magnetic resonance imaging agents

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012529500A (ja) * 2009-06-12 2012-11-22 エラスムス・ユニヴァーシティ・メディカル・センター・ロッテルダム 癌の光線力学療法のための標的化されたナノフォトメディスン

Also Published As

Publication number Publication date
WO2006060797A3 (en) 2006-08-24
CA2589881A1 (en) 2006-06-08
WO2006060797A2 (en) 2006-06-08
AU2005311560A1 (en) 2006-06-08
KR20070086803A (ko) 2007-08-27
US20090076571A1 (en) 2009-03-19
EP1830879A4 (en) 2008-09-17
DE602005024437D1 (de) 2010-12-09
EP1830879A2 (en) 2007-09-12
EP1830879B1 (en) 2010-10-27
ATE485836T1 (de) 2010-11-15

Similar Documents

Publication Publication Date Title
Liang et al. Theranostic porphyrin dyad nanoparticles for magnetic resonance imaging guided photodynamic therapy
US8323621B2 (en) Multi-use multimodal imaging chelates
Zhu et al. Hyperbranched polymers for bioimaging
Yin et al. Tongue cancer tailored photosensitizers for NIR-II fluorescence imaging guided precise treatment
Duo et al. Patient-derived microvesicles/AIE luminogen hybrid system for personalized sonodynamic cancer therapy in patient-derived xenograft models
JP6585504B2 (ja) ポルフィリン修飾されたテロデンドリマー
CN107057398B (zh) 一种七甲川菁荧光染料及其肿瘤精准诊断和治疗的应用
US20090311182A1 (en) Macromolecular Delivery Systems for Non-Invasive Imaging, Evaluation and Treatment of Arthritis and Other Inflammatory Diseases
Sun et al. Degradable FeCuS-lipid nanoparticles confer ultrasound-activated CO release and O2-independent radical production for synergistic therapy
JPH10500659A (ja) 改善された官能性を有するテキサフィリン金属錯体
Jibin et al. Nanohybrids of magnetically intercalated optical metamaterials for magnetic resonance/Raman imaging and in situ chemodynamic/photothermal therapy
US20110110866A1 (en) Elastin-like polypeptide and gadolinium conjugate for magnetic resonance imaging
Tang et al. Near-infrared light-activated red-emitting upconverting nanoplatform for T1-weighted magnetic resonance imaging and photodynamic therapy
Vaidya et al. Contrast enhanced MRI‐guided photodynamic therapy for site‐specific cancer treatment
WO2009038776A1 (en) Therapeutic nanoconjugates
CN110856750B (zh) pH敏感缀合物、胶束及其制备方法和用途
Lee et al. Supramolecular assembly based on host–guest interaction between beta-cyclodextrin and adamantane for specifically targeted cancer imaging
Wang et al. Folic Acid–Conjugated Pyropheophorbide a as the Photosensitizer Tested for In Vivo Targeted Photodynamic Therapy
JP2008522666A (ja) 癌のためのｍｒｉガイド下光線力学的療法
Ding et al. NIR-II-triggered photothermal therapy with Au@ PDA/PEG-PI for targeted downregulation of PSMA in prostate cancer
JP2022525791A (ja) 光免疫療法およびそれに用いる薬剤
Zhang et al. Peptide-IR820 conjugate: a promising strategy for efficient vascular disruption and hypoxia induction in melanoma
CN107337685B (zh) 叶酸靶向Pyro光敏的合成和应用
KR100911250B1 (ko) 신규한 클로린 ｅ６-엽산 결합 화합물의 제조방법
US20240123092A1 (en) Photosensitizer-peptide conjugate with cleavable linker, and composition for photodynamic diagnosis or treatment comprising same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081202

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20100806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100806